24
Participants
Start Date
April 1, 2023
Primary Completion Date
April 1, 2025
Study Completion Date
November 1, 2025
Pramipexole
Participants will be started on 0.125 mg pramipexole for the first week. If this dose is well tolerated but not effective, the dose can be increased to 0.25 mg for the following week. If this dose is well tolerated but not effective, the dose can be further increased to 0.5 mg for the remainder of the 2-month period.
Placebo
Matching placebo
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
University Medical Center of Amsterdam, Amsterdam
European Leukodystrophy Association
OTHER
Massachusetts General Hospital
OTHER